The Echosens Blueprint: A Top Workplace as a Growth Engine

WESTBOROUGH, MA – December 08, 2025 – In the hyper-competitive world of medical technology, where the race for the next breakthrough is relentless, a company’s most valuable asset is often found far from the lab bench or the production line. For Echosens, a global leader in non-invasive liver diagnostics, this asset is its culture—an engine so powerful it has now been recognized by The Boston Globe as one of Massachusetts' Top Places to Work for the second consecutive year.

This is not a mere HR accolade; it is a strategic differentiator. In an industry grappling with high turnover and a fierce war for specialized talent, Echosens’ repeat recognition points to a sustainable model where employee well-being is inextricably linked to market disruption. The award, based on confidential employee feedback analyzed by survey partner Energage, evaluates everything from a shared belief in the company’s direction to opportunities for growth and the quality of management. Echosens’ consistent high marks, placing it among peers like HubSpot and Akamai Technologies, signal a deep alignment between its mission and its people.

“What ultimately makes Echosens an exceptional place to work is the shared sense of purpose across the team,” said Jon Gingrich, CEO of Echosens North America, in a statement. “People here believe in what we're doing—enabling better liver health outcomes—and they know their work makes a real difference in the lives of millions of people.”

This sentiment cuts to the core of the company’s success. The blueprint isn't just about perks; it's about purpose.

From Internal Culture to External Innovation

A positive internal culture is a laudable goal, but for a company like Echosens, it is the direct fuel for its innovation pipeline. The company’s core product, the FibroScan®, has already revolutionized liver health by providing a non-invasive alternative to painful biopsies, a technology validated by over 5,600 peer-reviewed publications. Yet, a motivated and engaged workforce does not rest on its laurels.

In the past 18 months, the company’s pace of innovation has been remarkable. In May 2024, it launched the next-generation FibroScan, featuring Guided VCTE™ technology to enhance the efficiency and standardization of liver scanning. This was followed by the global rollout of its cloud-based Liver Health Management (LHM) platform in November 2024, a system designed to streamline care by integrating diagnostic data for healthcare providers. These advancements are not developed in a vacuum; they are the product of a collaborative, supportive environment where employees feel empowered to solve complex problems.

This culture of continuous improvement directly addresses a looming global health crisis. With rates of metabolic dysfunction-associated steatotic liver disease (MASLD) and its more severe form, MASH, on the rise, the need for effective diagnostic and monitoring tools is urgent. Echosens is at the forefront of this battle, evidenced by its strengthened partnerships with pharmaceutical giants like Novo Nordisk and Boehringer Ingelheim. These collaborations aim to accelerate MASH diagnosis and care, with FibroScan technology playing a pivotal role in identifying patients and tracking treatment efficacy. The company’s recent FDA acceptance of its Letter of Intent to qualify Liver Stiffness Measurement (LSM) as a surrogate endpoint in MASH clinical trials is a landmark achievement, promising to speed up the development of new therapies.

A Strategic Advantage in the MedTech Talent Wars

Securing top talent in the medical technology sector is a formidable challenge. The industry demands a rare blend of specialized skills in engineering, software development, AI, and regulatory affairs. High staff turnover is common, driven by burnout, competitive offers, and a lack of growth opportunities. Against this backdrop, Echosens’ ability to not only attract but retain and inspire its workforce for a sustained period is a masterclass in modern corporate strategy.

The company’s approach is multifaceted. Its corporate values—summarized by the acronym CHOICES (Courage, Humility, Open-mindedness, Innovation, Commitment, Environment, and Simplicity)—are more than just words on a poster. They are embedded in a leadership philosophy that emphasizes fairness, respect, and accessibility. Employees consistently praise the approachability of the leadership team and the focus on work-life balance, factors that directly combat the burnout so prevalent in high-stakes industries.

Furthermore, Echosens extends its commitment beyond its own walls. The company has earned a gold medal for its Environmental, Social, and Governance (ESG) program for the second time, placing it in the top 5% of over 100,000 companies assessed globally. This commitment to corporate social responsibility, from using green electricity to conducting carbon footprint audits, resonates with a modern workforce that increasingly seeks employers whose values align with their own.

By fostering an environment where employees feel valued and connected to a larger mission, Echosens has created a powerful retention tool. This stability allows for the long-term development of complex projects and builds a deep well of institutional knowledge—a competitive moat that is difficult for rivals to replicate. The result is a virtuous cycle: a great culture attracts great people, who in turn drive groundbreaking innovation, which reinforces the company’s mission and makes it an even more compelling place to work.

While many companies talk about putting people first, Echosens is demonstrating how to translate that principle into tangible market leadership and profound global health impact. Its success serves as a powerful case study for any organization aiming to thrive in the 21st century. For Echosens, the formula is clear: investing in people is the most direct path to pioneering the future of patient care.